Skip to main content

3 Result(s)

within Britta Kehden Remove this filter Cancer Research Remove this filter Intensive / Critical Care Medicine Remove this filter

and

  1. Article

    Open Access

    Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

    Thomas Burmeister, Aeint-Steffen Ströh, Britta Kehden, Heiko Trautmann… in Leukemia (2024)

    Download PDF (1088 KB) View Article

  2. No Access

    Article

    Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia

    Michaela Kotrova, Antonia Volland, Britta Kehden, Heiko Trautmann… in Leukemia (2020)

  3. Article

    Open Access

    MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

    We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received ...

    Christiane Pott, Laurie H. Sehn, David Belada, John Gribben, Eva Hoster… in Leukemia (2020)

    Download PDF (1496 KB) View Article